Table 2: Comparison of low versus high counts of infiltrating immune cells in OSCC patients* with and without high-endothelial venules (HEV) using Fisher's exact test.

	All tumors			T1/T2	T3/T4					
	HEV+	HEV-		all HEV+	all (HEV+/-)		HEV+		HEV-	
	no. (%)	no. (%)	P	no. (%)	no (%)	P	no. (%)	P	no. (%)	P
CD3										
Low	15 (22.4)	6 (85.7)	**0.002**	11 (21.2)	10 (47.6)	**0.026**	4 (28.6)	0.396	6 (85.7)	**0.002**
High	52 (77.6)	1 (14.3)		41 (78.8)	11 (52.4)		10 (71.4)		1 (14.3)	
CD4										
Low	44 (65.7)	5 (100.0)	0.170	34 (65.4)	14 (73.7)	0.359	9 (64.3)	0.587	5 (100.0)	0.138
High	23 (34.3)	0 (0.0)		18 (34.6)	5 (26.3)		5 (35.7)		0 (0.0)	
CD8										
Low	35 (52.2)	5 (100.0)	0.061	28 (53.8)	12 (63.2)	0.336	7 (50.0)	0.517	5 (100.0)	0.057
High	32 (47.8)	0 (0.0)		24 (46.2)	7 (36.8)		7 (50.0)		0 (0.0)	
CD20										
Low	26 (38.2)	6 (85.7)	**0.038**	20 (37.7)	12 (57.1)	0.104	6 (42.9)	0.478	6 (85.7)	**0.022**
High	42 (61.8)	1 (14.3)		33 (62.3)	9 (42.9)		8 (57.1)		1 (14.3)	
CD68										
Low	33 (48.5)	6 (85.7)	0.109	22 (41.5)	17 (81.0)	**0.002**	11 (78.6)	**0.014**	6 (85.7)	**0.034**
High	35 (51.5)	1 (14.3)		31 (58.5)	4 (19.0)		3 (21.4)		1 (14.3)	
DC-lamp										
Low	32 (51.6)	5 (71.4)	0.279	25 (53.2)	11 (52.4)	0.579	6 (42.9)	0.354	5 (71.4)	0.314
High	30 (48.4)	2 (28.6)		22 (46.8)	10 (47.6)		8 (57.1)		2 (28.6)	
Eosinophils										
Low	37 (55.2)	6 (85.7)	0.227	26 (50.0)	16 (76.2)	**0.035**	10 (71.4)	0.129	6 (85.7)	0.082
High	30 (44.8)	1 (14.3)		26 (50.0)	5 (23.8)		4 (28.6)		1 (14.3)	
Mast cells										
Low	32 (47.8)	6 (85.7)	0.108	25 (48.1)	13 (61.9)	0.209	7 (50.0)	0.568	6 (85.7)	0.068
High	35 (52.2)	1 (14.3)		27 (51.9)	8 (38.1)		7 (50.0)		1 (14.3)	
PD-L1										
Low	23 (59.0)	4 (66.7)	0.544	15 (50.0)	12 (85.7)	**0.024**	8 (100.0)	**0.010**	4 (66.7)	0.386
High	16 (41.0)	2 (33.3)		15 (50.0)	2 (14.3)		0 (0.0)		2 (33.3)	

* Analyses for CD3+ cells, eosinophils and mast cells were carried out in 74 patients, for CD4+ and CD8+ cells in 72 patients, for DC-lamp+ cells in 69 patients and for PD-L1+ cells in 45 patients. All other analyses included 75 patients.